What Causes Breakthrough Hemolysis in PNH? Key Triggers
At a Glance
Breakthrough hemolysis in PNH occurs when complement activity overwhelms a complement inhibitor or medication levels fall too low. Infections, surgery, pregnancy, and delayed doses are common triggers, so urgent symptoms require prompt medical attention.
In this answer
4 sections
Breakthrough hemolysis is a sudden return of red blood cell destruction (hemolysis) in people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are already on a stable treatment regimen, such as a complement inhibitor medication [1]. While these medications are highly effective at protecting your red blood cells, their protection can sometimes be overwhelmed by physical stress or by the drug dropping to low levels in your bloodstream [2][3]. When this happens, a sudden return of PNH symptoms can occur. The most common causes of breakthrough hemolysis include infections, major physical stress (like surgery), pregnancy, or a delay in receiving your PNH medication [4][2][5].
How It Happens
To understand why breakthrough hemolysis happens, it helps to briefly recall how PNH affects your blood. PNH red blood cells are missing protective proteins on their surface called CD55 and CD59 [6]. Without these, your red blood cells are highly vulnerable to being attacked by the complement system, a part of your immune system that normally fights off invaders [6].
Complement inhibitor drugs (like eculizumab, ravulizumab, pegcetacoplan, or iptacopan) act to block specific parts of the complement system [7]. However, they block different steps, and two main situations can cause their protection to fail:
- The complement system goes into overdrive (Pharmacodynamic Breakthrough): When your body faces a severe stressor like an infection or surgery, your immune system revs up to protect you [4]. This intense immune response can overwhelm your medication, leading to red blood cell destruction even if you took your medicine exactly on time and have the right amount in your body [2].
- Medication levels drop too low (Pharmacokinetic Breakthrough): If there isn’t enough medication in your bloodstream to keep the complement system suppressed, your vulnerable red blood cells will be attacked [3].
Common Triggers of Breakthrough Hemolysis
Knowing the triggers can help you and your doctor anticipate a breakthrough event and adjust your treatment or monitoring if necessary.
1. Infections and Illnesses
Infections are the most common trigger for breakthrough hemolysis, accounting for more than half of these events in some studies [8]. Whether it’s a common cold, the flu, a stomach bug, or COVID-19, an infection activates your complement system [4]. Even with adequate medication in your system, this activation can override the drug’s protection.
Important Note on Vaccines: Because complement inhibitors suppress part of your immune system, preventing infections through vaccination is incredibly important, particularly against dangerous bacteria like meningococcus. While the immune response to a vaccine can occasionally act as a temporary trigger for a mild breakthrough event, this risk is uncommon [2]. The life-saving benefit of preventing a severe infection far outweighs this risk. Never skip or delay a recommended vaccine without speaking to your hematologist.
2. Surgery and Physical Trauma
Major physical stress, such as a scheduled surgery, emergency operation, or serious physical injury, causes inflammation and ramps up the complement system [2]. Because of this risk, surgeries and even dental procedures must be carefully planned in advance with your hematology team to ensure your medication levels are optimized.
3. Missing or Delaying a Dose
Complement inhibitors are processed by the body over a specific amount of time. Delaying a dose—whether due to pharmacy delays, insurance issues, or simply forgetting—can cause the level of medication in your blood to dip below the protective threshold [9]. The consequences of a delay vary greatly depending on which specific medication you take (e.g., a daily pill vs. an infusion every 8 weeks) [8]. Always follow your specific drug’s missed-dose plan.
4. Pregnancy
Pregnancy naturally increases complement system activity and can also change how your body processes and clears medications [10]. Some pregnant people with PNH experience breakthrough hemolysis because their standard drug dose is no longer enough to maintain the required protective levels in their blood [5]. Pregnancy planning should always involve both your hematologist and a high-risk obstetric specialist to closely monitor your medication levels and protect your health.
Signs and Symptoms to Watch For
Breakthrough hemolysis can be dangerous because it can lead to acute kidney injury or increase your risk of life-threatening blood clots (thrombosis) [11][12]. Note that a breakthrough can happen without visible dark urine, so you should not wait for that sign to seek help [1].
Seek EMERGENCY medical care (Call 911 or go to the ER) if you experience:
- Chest pain or sudden shortness of breath
- Severe or unusual abdominal pain
- Fainting, confusion, or new neurologic symptoms (like weakness on one side of your body)
- A sudden, severe drop in urine output
- Fever, severe headache, neck stiffness, vomiting, or a new rash (these can be signs of a meningococcal infection, which is a medical emergency for anyone taking a complement inhibitor).
Contact your hematology team promptly if you experience:
- Dark or red urine (which may indicate hemoglobinuria, though this can also be caused by dehydration or other factors) [1]
- A sudden increase in fatigue or weakness
- A return of your typical PNH symptoms that you experienced before starting medication
What to Do Next
If you suspect you are having a breakthrough event, contact your hematology team immediately. Do not attempt to change your dosage or take extra medication on your own.
Your doctor will likely run blood tests to look at your full clinical picture. While they will check your LDH (a marker of red blood cell destruction) and hemoglobin, they may also check your bilirubin, reticulocytes, haptoglobin, and kidney function to see if the hemolysis is happening inside your blood vessels (intravascular) or elsewhere in your body (extravascular) [1][3].
Depending on your specific medication, the trigger, and the severity of the event, your medical team will create a tailored rescue plan. This might include treating an underlying infection, offering supportive care for your kidneys, providing a blood transfusion, or adjusting your PNH medication schedule under strict specialist supervision [2][5].
Common questions in this guide
What are the most common causes of breakthrough hemolysis in PNH?
Can breakthrough hemolysis happen even when I have taken my PNH medicine on time?
What should I do if my PNH dose or infusion is delayed?
Which symptoms of breakthrough hemolysis are an emergency?
How do doctors check for breakthrough hemolysis in PNH?
Does pregnancy increase the risk of breakthrough hemolysis in PNH?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Paroxysmal nocturnal hemoglobinuria.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What symptoms require emergency services (911/ER) rather than a call to the clinic?
- 2.What is my medication-specific rescue plan if I experience breakthrough hemolysis?
- 3.How will we tell if my symptoms are due to intravascular hemolysis, extravascular hemolysis, or something else entirely?
- 4.What should I do if an infusion, prescription, or dose is delayed for reasons outside my control (like an insurance issue)?
- 5.Do I need any specific blood work (like LDH or hemoglobin) during a routine illness like a cold?
References
References (12)
- 1
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I, Sierra JR, Johnston KM, et al.
Hematology (Amsterdam, Netherlands) 2020; (25(1)):327-334 doi:10.1080/16078454.2020.1807226.
PMID: 32856539 - 2
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
Dingli D, De Castro Iii C, Koprivnikar J, et al.
Hematology (Amsterdam, Netherlands) 2024; (29(1)):2329030 doi:10.1080/16078454.2024.2329030.
PMID: 39665683 - 3
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al.
Haematologica 2021; (106(1)):230-237 doi:10.3324/haematol.2019.236877.
PMID: 31949012 - 4
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ, Höchsmann B, Dopler A, et al.
Frontiers in immunology 2019; (10()):1639 doi:10.3389/fimmu.2019.01639.
PMID: 31379839 - 5
Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis.
Sharma R, Keyzner A, Liu J, et al.
Leukemia research reports 2015; (4(1)):36-8 doi:10.1016/j.lrr.2015.05.001.
PMID: 26052501 - 6
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM, Frieri C, Urciuoli E, Marano L
Immunological reviews 2023; (313(1)):262-278 doi:10.1111/imr.13137.
PMID: 36110036 - 7
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M, Rondelli T, Ricci P, et al.
Journal of hematology & oncology 2017; (10(1)):126 doi:10.1186/s13045-017-0496-x.
PMID: 28629435 - 8
Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.
Fattizzo B, Pedone GL, Metafuni E, et al.
American journal of hematology 2025; (100(11)):1963-1971 doi:10.1002/ajh.70032.
PMID: 40785544 - 9
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Nakayama H, Usuki K, Echizen H, et al.
Biological & pharmaceutical bulletin 2016; (39(2)):285-8 doi:10.1248/bpb.b15-00703.
PMID: 26830487 - 10
Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
Miyasaka N, Miura O, Kawaguchi T, et al.
International journal of hematology 2016; (103(6)):703-12 doi:10.1007/s12185-016-1946-x.
PMID: 26857155 - 11
Hemosiderin tubulopathy-induced acute kidney injury - A rare initial manifestation of paroxysmal nocturnal hemoglobinuria.
Rao SP, Laxminarayana SLK, Nagaraju SP, et al.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2018; (29(5)):1232-1236 doi:10.4103/1319-2442.243958.
PMID: 30381527 - 12
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.
Kokoris S, Polyviou A, Evangelidis P, et al.
International journal of molecular sciences 2024; (25(22)) doi:10.3390/ijms252212104.
PMID: 39596172
This page explains possible triggers and warning signs of breakthrough hemolysis in PNH for informational purposes only and does not constitute medical advice. Contact your hematology team for individualized instructions, and seek emergency care for urgent symptoms.